FDA Opens Public Docket on VOQUEZNA Exclusivity as ANDA Fight Escalates
PHAT is trading near its 52-week low of $5.015 (9.7% above the low) on elevated volume (3.3× avg).
Summary
The FDA opened a public comment docket on the legal issues in the ANDA litigation over VOQUEZNA's new chemical entity exclusivity, with comments due Nov. 23, 2026. Phathom has moved to intervene, and a second ANDA filer may seek to consolidate the case. This follows BDR Pharmaceuticals' suit against the FDA challenging the GAIN Act extension of VOQUEZNA's exclusivity, disclosed in the Oct. 23 8-K. The stakes are the exclusivity Phathom says runs through May 3, 2032 — it underpins pricing and the revenue ramp that produced $74.3M in Q2 revenue. An adverse ruling or FDA reversal would pull forward generic competition; the Nov. 23 comment deadline is the next dated checkpoint.
At the time of this announcement, PHAT was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.4M. The 52-week trading range was $5.02 to $18.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.